Innocare's New Drug Application for Orelabrutinib in ITP Accepted for Review by NMPA

Stock News05-28

Innocare Pharma Limited (688428.SH) announced that the New Drug Application (NDA) for its self-developed Bruton's tyrosine kinase (BTK) inhibitor, orelabrutinib, intended for the treatment of patients with primary immune thrombocytopenia (ITP), has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). Orelabrutinib is a novel, highly target-selective BTK inhibitor independently developed by the company. BTK is a key kinase in the B-cell receptor signaling pathway, crucial for the activation of B lymphocytes, macrophages, and other immune cells, as well as for the production of pathogenic antibodies involved in the pathological process of ITP.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136555407?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 16:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136555407","market":"us","top_or_hot":-1,"title":"Innocare's New Drug Application for Orelabrutinib in ITP Accepted for Review by NMPA","media":"Stock News","content":"<p>Innocare Pharma Limited (688428.SH) announced that the New Drug Application (NDA) for its self-developed Bruton's tyrosine kinase (BTK) inhibitor, orelabrutinib, intended for the treatment of patients with primary immune thrombocytopenia (ITP), has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). Orelabrutinib is a novel, highly target-selective BTK inhibitor independently developed by the company. BTK is a key kinase in the B-cell receptor signaling pathway, crucial for the activation of B lymphocytes, macrophages, and other immune cells, as well as for the production of pathogenic antibodies involved in the pathological process of ITP.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innocare's New Drug Application for Orelabrutinib in ITP Accepted for Review by NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnocare's New Drug Application for Orelabrutinib in ITP Accepted for Review by NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-28 16:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Innocare Pharma Limited (688428.SH) announced that the New Drug Application (NDA) for its self-developed Bruton's tyrosine kinase (BTK) inhibitor, orelabrutinib, intended for the treatment of patients with primary immune thrombocytopenia (ITP), has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). Orelabrutinib is a novel, highly target-selective BTK inhibitor independently developed by the company. BTK is a key kinase in the B-cell receptor signaling pathway, crucial for the activation of B lymphocytes, macrophages, and other immune cells, as well as for the production of pathogenic antibodies involved in the pathological process of ITP.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1136555407","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136555407","pubTimestamp":1779956955,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Innocare Pharma Limited (688428.SH) announced that the New Drug Application (NDA) for its self-developed Bruton's tyrosine kinase (BTK) inhibitor, orelabrutinib, intended for the treatment of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","BK0239":"医药制造","BK1574":"生物医药B类股","BK1161":"生物科技","IPOS":"Renaissance International IPO ETF","09969":"诺诚健华"},"translate_title":"诺诚健华奥布替尼治疗ITP新药申请获NMPA受理审评","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":1,"09969":1,"IPOS":1},"content_text":"Innocare Pharma Limited (688428.SH) announced that the New Drug Application (NDA) for its self-developed Bruton's tyrosine kinase (BTK) inhibitor, orelabrutinib, intended for the treatment of patients with primary immune thrombocytopenia (ITP), has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). Orelabrutinib is a novel, highly target-selective BTK inhibitor independently developed by the company. BTK is a key kinase in the B-cell receptor signaling pathway, crucial for the activation of B lymphocytes, macrophages, and other immune cells, as well as for the production of pathogenic antibodies involved in the pathological process of ITP.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136555407","isCrawlerRequest":true}